In the first-line treatment of mUC, a high PD-L1 combined positive score (CPS) of ≥10%, defined as the percentage of tumour cells (TC) and immune cells (IC)/the total tumour cells given by the 22C3 Dako assay, was associated with a prolonged median OS (mOS) in patients ineligible for cisplatin treatment with first-line pembrolizumab in the single-arm phase II KEYNOTE 052 study. Here, CD274 is linked to neoplasm.